FDA approves nivolumab for esophageal squamous cell carcinom
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Food and Drug Administration approved nivolumab (OPDIVO, Bristol-Myers Squibb Co.) for patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.

• Efficacy was investigated in randomized, active-controlled, open-label trial in 419 patients with unresectable advanced, recurrent, or metastatic ESCC.

• The most common adverse reactions in ³ 10% patients receiving nivolumab were rash, decreased appetite, diarrhea, constipation, musculoskeletal pain, upper respiratory tract infection, cough, pyrexia, pneumonia, anemia, fatigue, pruritus, nausea, and hypothyroidism.

• The recommended nivolumab dose for ESCC is 240 mg every 2 weeks or 480 mg every 4 weeks.

Source: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-nivolumab-esophageal-squamous-cell-carcinoma
Like
Comment
Share